Enhanced potential for oxidative stress in livers of senescent rats by the peroxisome proliferator-activated receptor alpha agonist perfluorooctanoic acid

Aging sensitizes the liver to the hepatocarcinogenic effect of PPARalpha agonists via unknown mechanisms. This study was designed to investigate age-dependent, hepatic effects of the non-metabolizable PPARalpha agonist perfluorooctanoic acid (PFOA) on the delicate balance between activities of pathways involved in H(2)O(2) production and elimination. Male Fischer-344 rats, ranging in age from juvenile (4 weeks old), post puberty (10 weeks old), mature adulthood (20 weeks old), middle age (50 weeks old), to senescence (100 weeks old), were treated intragastrically with either 150mg PFOA/kg in 0.5ml corn oil, or with corn oil alone. Animals were sacrificed at predetermined time-points ranging from 0-28 days post PFOA or oil administration. Hepatic peroxisomal beta-oxidizing activities were significantly elevated (four- to six-fold) in all age groups by PFOA. While levels declined to near basal values within 3-7 days in 4 and 10, they remained elevated for an additional week in 20-, 50- and 100-week-old rats. However, catalase activity was significantly lower in senescent livers compared with all other groups. In conclusion, aging does not appear to hinder the capacity of the liver to produce excess H(2)O(2) through peroxisomal beta-oxidation upon exposure to PPAR agonists. However, the reduced ability of the senescent liver to recover from PFOA-induced potential increase in H(2)O(2) production, coupled with the apparent diminished capacity of this liver to decompose H(2)O(2), enhances the potential for hepatic oxidative damage in aged animals. This may explain the enhanced susceptibility of the senescent liver to the hepatocarcinogenic effect of PPAR agonists.

[1]  P. Southorn,et al.  Free radicals in medicine. II. Involvement in human disease. , 1988, Mayo Clinic proceedings.

[2]  G. Sobue,et al.  Lipid peroxidation and advanced glycation end products in the brain in normal aging and in Alzheimer's disease , 2002, Acta Neuropathologica.

[3]  Reddy Jk,et al.  Carcinogenesis by Hepatic Peroxisome Proliferators: Evaluation of the Risk of Hypolipidemic Drugs and Industrial Plasticizers to Humans , 1983 .

[4]  R. Cattley,et al.  Age-related susceptibility to the carcinogenic effect of the peroxisome proliferator WY-14,643 in rat liver. , 1991, Carcinogenesis.

[5]  Sang-Oh Yoon,et al.  Dose effect of oxidative stress on signal transduction in aging , 2002, Mechanisms of Ageing and Development.

[6]  M. Badr,et al.  Biology of senescent liver peroxisomes: role in hepatocellular aging and disease. , 1999, Environmental health perspectives.

[7]  R. Melnick,et al.  In vitro steady-state levels of hydrogen peroxide after exposure of male F344 rats and female B6C3F1 mice to hepatic peroxisome proliferators. , 1986, Carcinogenesis.

[8]  J. Morrow,et al.  The isoprostanes. Current knowledge and directions for future research. , 1996, Biochemical pharmacology.

[9]  J. Carlson,et al.  Changes in superoxide radical and lipid peroxide formation in the brain, heart and liver during the lifetime of the rat , 1987, Mechanisms of Ageing and Development.

[10]  R. Schulte‐Hermann,et al.  Increased susceptibility of aged rats to hepatocarcinogenesis by the peroxisome proliferator nafenopin and the possible involvement of altered liver foci occurring spontaneously. , 1991, Cancer research.

[11]  R. Thurman,et al.  Induction of peroxisomes by treatment with perfluorooctanoate does not increase rates of H2O2 production in intact liver. , 1992, Toxicology letters.

[12]  David J. Waxman,et al.  trans-activation of PPARα and PPARγ by structurally diverse environmental chemicals , 1999 .

[13]  S A Qureshi,et al.  Development of hepatocellular carcinomas and increased peroxisomal fatty acid beta-oxidation in rats fed [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (Wy-14,643) in the semipurified diet. , 1981, Carcinogenesis.

[14]  M. Badr,et al.  Enhanced Hepatocarcinogenicity Due to Agonists of Peroxisome Proliferator-Activated Receptors in Senescent Rats: Role of Peroxisome Proliferation, Cell Proliferation, and Apoptosis , 2002, TheScientificWorldJournal.

[15]  B. Halliwell,et al.  Role of free radicals and catalytic metal ions in human disease: an overview. , 1990, Methods in enzymology.

[16]  S. Shack,et al.  Loss in oxidative stress tolerance with aging linked to reduced extracellular signal‐regulated kinase and Akt kinase activities , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  M. Rao,et al.  Mitogenic effect in mouse liver induced by a hypolipidemic drug, nafenopin , 1977, Virchows Archiv. B, Cell pathology.

[18]  H. Shio,et al.  Specificity in the action of hypolipidemic drugs: increase of peroxisomal beta-oxidation largely dissociated from hepatomegaly and peroxisome proliferation in the rat. , 1982, Journal of lipid research.

[19]  R. Schulte‐Hermann,et al.  Role of oxidative stress in age dependent hepatocarcinogenesis by the peroxisome proliferator nafenopin in the rat. , 1991, Cancer research.

[20]  C. Duve,et al.  A fatty acyl-CoA oxidizing system in rat liver peroxisomes; enhancement by clofibrate, a hypolipidemic drug. , 1976, Proceedings of the National Academy of Sciences of the United States of America.